Atreca, Inc.

Good day and thank you for standing by. Welcome to the TRICA fourth quarter and four-year financial results conference call. At this time, all participants are in listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you need to press star one on your telephone. If you require any further assistance, please press star zero. I want to hand the conference over to your speaker today, Alex Gray, Head of Investor Relations. Please go ahead.

Thank you, operator, and thank you to those joining us today. We are pleased to be hosting a year-end conference call and webcast, including updated data from our ongoing Phase 1B trial of ATRC 101. Joining me for the repair remarks are John Orwin, CEO, and Dr. Jonathan Benjamin, Senior Vice President of Clinical Research. Also on the line are Dr. Tito Serafini, Chief Strategy Officer and Atreka founder, and Herb Cross, CFO. We'll each be available during the Q&A sessions. those joining by phone, I'd note that we are presenting slides as part of today's program, which can be viewed via the webcast posted to the events and presentations section of our Investor Relations website at ir.atraca.com. An archived replay of today's webcast and the accompanying slides will be available on our IR site following the live presentation. During today's call, we make forward-looking statements based on current expectations. These statements are subject to a number of significant risks and uncertainties, and our actual results may differ materially. the disclosure in the accompanying slides, our most recent Forms 10-K and 10-Q, and the reports that we may file on Form 8-K with the Securities and Exchange Commission. All our statements are made as of today, March 3, 2022, based on information currently available to us. We can give no assurance these statements will prove to be correct. We undertake no duty to update these statements, except as required by law. I'll now turn it over to John Orwell. John?

Thank you, Alex. Before discussing the agenda, I'd like to briefly address the purpose of this call. Based on the ATRC 101 trial results we've begun to see and their impact on our clinical strategy, we're providing updated data along with our year-end earnings. We will continue to provide enrollment updates in our earnings reports going forward, but we do not yet plan to host regular quarterly conference calls, and future data presentations will be timed around key clinical of the second half of the year. On today's call, Jonathan will present data from the ATRC-101 monotherapy and pembrolizumab combination cohorts in our ongoing first-in-human phase 1b trial, evaluating ATRC-101 in participants with select solid tumor cancers, followed by an update on our clinical strategy for 101. I will then discuss our financials and upcoming milestones before opening the line for Q&A. Top line summary is that ATRC-101 is demonstrating anti-tumor activity in participants with ATRC-101 target expression, including responses by resist, both as monotherapy and in combination with numberless meth. And it was well tolerated at all doses and dosing frequencies evaluated. So from each of the major points in turn, the primary objective of the Phase 1B study is to evaluate safety, We're pleased to share that the ATRC-101 so far has been well tolerated in both monotherapy and the combination arm, including at the highest dose study of 30 milligrams per kilogram administered both on a once-every-two-week and a once-every-three-week dosing schedule. As a reminder, ATRC-101 targets a novel ribonucleoprotein complex, and we continue to see significant association between target expression and anti-tumor activity. We have now validated this platform-derived target, as well as a diagnostic for participant selection, which we are proceeding with integrating into the trial protocol. Furthermore, we're excited to report that in this heterogeneous and heavily pre-treated participant group, we are seeing responses and stable beliefs with reduction in tumor burden across multiple cancer types in participants treated with monotherapy and combination therapy. We believe that these data, showing that our first clinical candidate acted, validate the ability of our platform to identify potentially valuable therapeutic antibodies, recognizing novel targets in oncology. I'll turn it over to Jonathan to discuss the data.